Status:
COMPLETED
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.
Lead Sponsor:
GlaxoSmithKline
Conditions:
Tetanus
Diphtheria
Eligibility:
All Genders
6-8 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and reactogenicity of booster dose of GSK Biologicals' dTpa vaccine (Boostrix) in Chinese children at 6-8 years of age.
Eligibility Criteria
Inclusion
- A male or female between, and including, 6-8 years of age at the time of vaccination,
- Written informed consent obtained from the parent or guardian of the subject,
- Subjects who have received a total of 4 doses of DTP vaccine in the first 2 years of life,
Exclusion
- subjects who have received previous DTP booster vaccination since administration of the fourth dose of vaccine in second year of life can not participate
- Subjects with history of diphtheria, pertussis or tetanus diseases can not participate
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00406562
Start Date
January 1 2007
End Date
February 1 2007
Last Update
October 27 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Suining, China